文献速递产科母胎医学

妊娠11周前开始低剂量阿司匹林是否降低子痫前期发生率

Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia?
PubMed 文献 · Am J Obstet Gynecol · 2019-09-05

该系统评价与Meta分析检索1985年至2018年11月的多个数据库,纳入8项随机对照试验共1426名参与者,评估妊娠11周前开始低剂量阿司匹林对子痫前期、妊娠期高血压等结局的影响。结果显示子痫前期风险降低未达统计学显著(RR 0.52,95%CI 0.23-1.17,P=.115),但早产风险降低有统计学意义(RR 0.52,95%CI 0.27-0.97,P=.040),胎儿生长受限无影响。

要点

  • 妊娠11周前开始低剂量阿司匹林与子痫前期风险降低无显著关联(RR 0.52,95%CI 0.23-1.17,P=.115)。
  • 早产风险降低有统计学意义(RR 0.52,95%CI 0.27-0.97,P=.040)。
  • 胎儿生长受限风险无显著改变(RR 1.10,95%CI 0.58-2.07,P=.775)。

核心结论

  • 在高危女性中于妊娠11周前开始低剂量阿司匹林不降低子痫前期、妊娠期高血压、任何妊娠期高血压疾病及胎儿生长受限的风险。
  • 但可能降低早产风险;需要更大规模的随机对照试验来证实这些发现。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE via PubMed、EMBASE、Cochrane Central Register of Controlled Trials (CENTRAL)、ClinicalTrials.gov及世界卫生组织国际临床试验注册平台1985年至2018年11月。
  • 纳入标准为随机对照试验,评估妊娠11周前开始阿司匹林预防子痫前期和/或妊娠期高血压疾病或改善复发性流产女性妊娠结局,与安慰剂或无治疗比较,且>85%研究人群有结局数据。
  • 共纳入8项随机对照试验,合计1426名参与者。

主要发现

  • 妊娠11周前开始低剂量阿司匹林与子痫前期风险降低无显著关联(RR 0.52,95%CI 0.23-1.17,P=.115)。
  • 与妊娠期高血压风险降低无显著关联(RR 0.49,95%CI 0.20-1.21,P=.121)。
  • 与任何妊娠期高血压疾病风险降低无显著关联(RR 0.59,95%CI 0.33-1.04,P=.067)。
  • 降低早产风险(RR 0.52,95%CI 0.27-0.97,P=.040)。
  • 对胎儿生长受限风险无影响(RR 1.10,95%CI 0.58-2.07,P=.775)。

关键数值与推荐

  • 采用随机效应Meta分析,按研究规模加权,计算相对风险(RR)及95%置信区间。
  • 异质性评估使用χ2统计量、I2和Tau2;I2>50%且Tau2>0或χ2检验P<0.10认为异质性较大。
  • 因纳入研究数量少,未评估发表偏倚。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因纳入研究数量少,未评估发表偏倚。
  • 需要更大规模的随机对照试验来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE DATA: Preconception or early administration of low-dose aspirin might improve endometrial growth, placental vascularization, and organogenesis. Most studies have evaluated the potential benefit of preconception or early administration of low-dose aspirin in women with a history of recurrent pregnancy loss, women who have undergone in vitro fertilization, or women with thrombophilia or antiphospholipid syndrome. These women are at an increased risk of placenta-associated complications of pregnancy, including preeclampsia, preterm delivery, and fetal growth restriction. STUDY OUTCOMES: We performed a systematic review and meta-analysis to evaluate the effect of low-dose aspirin initiated at <11 weeks' gestation on the risk of preeclampsia, gestational hypertension, or any hypertensive disorder of pregnancy. Secondary outcomes included preterm delivery at <37 weeks' gestation and fetal growth restriction. STUDY APPRAISAL AND SYNTHESIS METHODS: We searched in MEDLINE via PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform from 1985 to November 2018. Entry criteria were randomized controlled trials evaluating the effect of aspirin administered at <11 weeks' gestation in preventing preeclampsia and/or hypertensive disorders in pregnancy or improving pregnancy outcomes in women with recurrent miscarriage as compared with placebo or no treatment and outcome data available or provided by authors for >85% of the study population. Relative risks with 95% confidence intervals were calculated for each study and pooled for global analysis as the effect measure. We assessed statistical heterogeneity in each meta-analysis using the χ2 statistics, I2, and Tau2. Heterogeneity was considered substantial if an I2 was greater than 50% and either the Tau2 was greater than zero or there was a low P value (<0.10) in the χ2 test for heterogeneity. Random-effects meta-analysis, weighted by the size of the studies, was performed to produce an overall summary on aspirin effect for each outcome. Sensitivity analysis by sequential omission of each individual study and by fixed-effects model was performed. Publication bias was not assessed because of the small number of included studies. Statistical analysis was performed using Stata release 14.0 (StataCorp). RESULTS: The entry criteria were fulfilled by 8 randomized controlled trials on a combined total of 1426 participants. Low-dose aspirin initiated at <11 weeks' gestation was associated with a nonsignificant reduction in the risk of preeclampsia (relative risk, 0.52; 95% confidence interval, 0.23-1.17, P = .115), gestational hypertension (relative risk, 0.49; 95% confidence interval, 0.20-1.21; P = .121), and any hypertensive disorder of pregnancy (relative risk, 0.59; 95% confidence interval, 0.33-1.04, P = .067). Early administration of low-dose aspirin reduced the risk of preterm delivery (relative risk, 0.52; 95% confidence interval, 0.27-0.97, P = .040) but had no impact on the risk of fetal growth restriction (relative risk, 1.10; 95% confidence interval, 0.58-2.07, P = .775). Except for preterm delivery and any hypertensive disorder of pregnancy, sensitivity analysis demonstrated similar observations, therefore confirming the robustness of the analysis. CONCLUSION: The administration of low-dose aspirin at <11 weeks' gestation in women at high risk does not decrease the risk of preeclampsia, gestational hypertension, any hypertensive disorder of pregnancy, and fetal growth restriction. However, it might reduce the risk of preterm delivery. Larger randomized controlled trials will be required to substantiate the findings.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chaemsaithong P, Cuenca-Gomez D, Plana MN, et al. Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia? Am J Obstet Gynecol. 2019. PMID: 31494125. doi:10.1016/j.ajog.2019.08.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。